Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Drugs under investigation for patients with MF who have failed treatment with JAK inhibitors

Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, gives an overview of agents that are currently being evaluated in patients with myelofibrosis (MF) who have failed treatment with JAK inhibitors, including parsaclisib, pelabresib, navitoclax, imetelstat, and navtedmadlin. This interview took place virtually.


Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.